Novotech is internationally recognized as the leading Asia Pacific-centered Biotech Contract Research Organization (CRO) with global execution capabilities.

Novotech is a clinical CRO with labs, phase I facilities, drug development consulting services, and FDA regulatory expertise and has experience in over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US, and Europe. Novotech has over 3000 staff globally and 34 office locations.


  • Take advantage of the world’s fastest-growing clinical trials region to accelerate your global clinical development by leveraging Novotech’s global footprint, relationships, and infrastructure.

  • Delve into the details of this full-service global product development and strategic regulatory group that has a proven track record of successful FDA meetings and approvals.

  • Get streamlined and integrated clinical trial services delivered by a dedicated team of professionals with deep industry and therapeutic area expertise across all phases of clinical development. 

  • Start getting accurate, high-quality, and timely biostatistics services delivered by this team of biostatisticians and statistical programmers, in addition to statistical planning, analysis, and reporting.

  • Novotech relies on years of experience, in-country knowledge, and real-life big data to identify and propose the best-performing sites. Uncover the possibilities for your next study.

  • Biotechnology companies are facing increased challenges around participant recruitment and retention, lengthy timeframes, and relatively high costs.

  • Our talented and experienced team can assist in all Clinical Study Phases (Phase 0, I, II and III) and in study designs ranging from First in Human (FIH), Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), Drug-Drug Interaction (DDI), Bioavailability/Bioequivalence (BA/BE), Food Effect as well as Special Population studies.

  • Novotech initiated the first national, privately owned, commercial Institutional Biosafety Committee (IBC) in Australia, successfully accredited by the Australian Office of the Gene Technology Regulator (OGTR).

  • Biotechnology companies consider locations in the Asia-Pacific region, such as South Korea and China to access vast treatment-naïve patient populations and accelerate their clinical trials at lower costs.

  • Many biotechnology companies look at the Asia-Pacific region for their trials in Infectious diseases and Vaccines due to the high prevalence of diseases such as Hepatitis (Hepatitis B, Hepatitis C), HIV, and Influenza across the region.

  • There may be as many as 8,000 rare diseases, affecting between 6% and 8% of the worldwide population in total. It is estimated there are about 30 million affected people in the EU and in North America, while over 45 million people may be suffering from a rare condition in Asia, with 10 million people in China alone.





235 Pyrmont Street, Level 3

Pyrmont, NSW 2009